Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DMT210 5% · 1 trial · 1 indication
Inflammatory lesion counts
Investigator Global Assessment (IGA)
5-point Clinical Erythema Assessment (CEA)
5-point Patient Severity Assessment of Erythema (PSA)
| Arm | Type | Description |
|---|---|---|
| DMT210 Topical Gel | EXPERIMENTAL | DMT210 Topical Gel 5% applied to the face twice daily for 12 weeks |
| Vehicle Control | PLACEBO_COMPARATOR | Topical Gel vehicle applied to the face twice daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| DMT210 Topical Gel 5% | DRUG | - |
| Vehicle Control | OTHER | - |
Inclusion Criteria: * Patient is male or non-pregnant female at least 18 years of age. * Clinical diagnosis of moderate to severe facial rosacea as determined by Investigator's Global Assessment (IGA) at Randomization * Patient has at least ten inflammatory lesions of rosacea on the face at Randomi...
DMT210 5% is an investigational small molecule topical gel being studied for the treatment of acne rosacea, a chronic inflammatory skin condition. It is in Phase 2 clinical development and is not yet approved by regulatory authorities.
DMT210 5% is being developed by Dermata Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol DRMA. The company is focused on developing novel treatments for dermatological conditions.
DMT210 5% is in Phase 2 clinical development. It has completed one Phase 2 trial, and it remains an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies for commercial use.
DMT210 5% has one completed clinical trial, NCT03003104, titled 'DMT210 Topical Gel in the Treatment of Acne Rosacea.' This was a Phase 2, randomized, double-blind, placebo-controlled study conducted in the United States with 107 participants aged 18 years and older.
The specific molecular target of DMT210 5% has not been disclosed. It is a small molecule topical gel being investigated for its potential to treat acne rosacea, but its mechanism of action is not publicly detailed.